Literature DB >> 8842476

Molecular staging of head and neck squamous carcinoma.

J A Brennan1, D Sidransky.   

Abstract

The staging system of head and neck cancer is a Tumor-Node-Metastases system that was developed by the American Joint Committee on Cancer. The stage of the head and neck cancer defines the extent of the lesion and is determined by physical examination, radiologic studies, and pathologic examination. Accurate staging of head and neck cancer is critical since it will determine the treatment modalities used to cure the disease. Recent advances in the field of molecular genetics have allowed clinicians to detect occult cancer cells previously missed by physical examination and standard histopathologic techniques. Molecular assays are 500 times more sensitive in identifying cancer cells than standard techniques and provide more objective analyses with fewer sampling errors. Consequently, these techniques are currently being used to perform molecular staging of head and neck cancer patients. Preliminary results show that molecular staging will accurately identify those patients at significantly increased risk for recurrence of their head and neck cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8842476     DOI: 10.1007/bf00049484

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  41 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  Carcinogens leave fingerprints.

Authors:  B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

Review 3.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

4.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

5.  Expression of p53 in premalignant and malignant squamous epithelium.

Authors:  B A Gusterson; R Anbazhagan; W Warren; C Midgely; D P Lane; M O'Hare; A Stamps; R Carter; H Jayatilake
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

6.  The incidence of p53 mutations increases with progression of head and neck cancer.

Authors:  J O Boyle; J Hakim; W Koch; P van der Riet; R H Hruban; R A Roa; R Correo; Y J Eby; J M Ruppert; D Sidransky
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens.

Authors:  A Puisieux; S Lim; J Groopman; M Ozturk
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

Review 8.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Clonal origin of bladder cancer.

Authors:  D Sidransky; P Frost; A Von Eschenbach; R Oyasu; A C Preisinger; B Vogelstein
Journal:  N Engl J Med       Date:  1992-03-12       Impact factor: 91.245

10.  Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers.

Authors:  M F Melhem; J C Law; L el-Ashmawy; J T Johnson; R J Landreneau; S Srivastava; T L Whiteside
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

View more
  2 in total

Review 1.  Detection of lymph node micrometastases in patients with squamous carcinoma of the head and neck.

Authors:  Alfio Ferlito; Alessandra Rinaldo; Kenneth O Devaney; Koh-ichi Nakashiro; Hiroyuki Hamakawa
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-04       Impact factor: 2.503

2.  The role of chromosomal aberrations in premalignant and malignant lesions in head and neck squamous cell carcinoma.

Authors:  Kamal-Eldin Ahmed Abou-Elhamd; Tito Naeem Habib
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-16       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.